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Introduction
Heterotrimeric G proteins are critical signal transducers of  activated G protein coupled receptors 
(GPCRs) (1). Gain-of-function mutations in several different Gα subunits — Gαs, Gαi, Gα12/13, and 
Gα11/q — are associated with a wide range of  human diseases. Two common sites of  mutation are 
G.hfs2.2 in switch 1 and G.s3h2.3 in switch 2 (Arg201 and Gln227 in Gαs, respectively) (2); such muta-
tions are highly activating in vitro and often oncogenic in vivo (2, 3). Activating point mutations at 
either of  these residues in Gαs cause a variety of  clinical manifestations, including pituitary, thyroid, 
and adrenal tumors, as well as McCune-Albright syndrome (3). Activating mutations at the correspond-
ing residues (Arg183 and Gln209) in either Gα11 or Gαq, are associated with ocular melanomas and 
congenital hemangioma, and those of  Gαq are associated with Sturge-Weber syndrome (4–7). These 
highly activating Gα mutations occur somatically and are presumably lethal in the germline (8). The 
only reported germline activating mutation in Gαs is Ala366Ser (G.s6h5.3), reported in 2 patients with 
testotoxicosis; in this case, the mutant allele is temperature sensitive and, thus, only stable and active at 
the lower temperature of  the testes (9).
Recently, we and others identified germline gain-of-function mutations in Gα11, encoded by the 
GNA11 gene, in families with autosomal-dominant hypocalcemia type 2 (ADH2) (10–14). To date, 6 such 
mutations have been uncovered in ADH2 patients (10–14). These mutations show weak effects in vitro 
when compared with the highly activating mutations discussed above (12). The principal phenotype in 
Heterotrimeric G proteins play critical roles in transducing extracellular signals generated by 
7-transmembrane domain receptors. Somatic gain-of-function mutations in G protein α subunits 
are associated with a variety of diseases. Recently, we identified gain-of-function mutations in 
Gα11 in patients with autosomal-dominant hypocalcemia type 2 (ADH2), an inherited disorder 
of hypocalcemia, low parathyroid hormone (PTH), and hyperphosphatemia. We have generated 
knockin mice harboring the point mutation GNA11 c.C178T (p.Arg60Cys) identified in ADH2 
patients. The mutant mice faithfully replicated human ADH2. They also exhibited low bone 
mineral density and increased skin pigmentation. Treatment with NPS 2143, a negative allosteric 
modulator of the calcium-sensing receptor (CASR), increased PTH and calcium concentrations in 
WT and mutant mice, suggesting that the gain-of-function effect of GNA11R6OC is partly dependent 
on coupling to the CASR. Treatment with the Gα11/q-specific inhibitor YM-254890 increased blood 
calcium in heterozygous but not in homozygous GNA11R60C mice, consistent with published crystal 
structure data showing that Arg60 forms a critical contact with YM-254890. This animal model of 
ADH2 provides insights into molecular mechanism of this G protein–related disease and potential 
paths toward new lines of therapy.
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the patients with these Gα11 muta-
tions is a perturbation in calcium 
homeostasis. The clinical findings 
of  ADH2 implicate the involvement 
of  the calcium-sensing receptor 
(CASR), which can couple to sever-
al G proteins, including Gα11, and is expressed on the surface of  the parathyroid chief  cells. Activation of  
the CASR suppresses production and secretion of  parathyroid hormone (PTH), a principal calcium-reg-
ulating hormone that increases blood calcium through effects on bone and kidney (15, 16). Activating 
mutations in CASR cause ADH1, in which hypocalcemia is observed with inappropriately low circulating 
PTH levels, resembling the clinical phenotype of  ADH2 (17). The CASR is also expressed in the renal 
distal tubule, where it acts independently of  PTH to promote calcium excretion (18). Consequently, a 
further complication of  ADH1 is hypercalciuria, which results from the combined effects of  reduced PTH 
signaling and increased CASR signaling in the renal distal tubule cells (19).
The GNA11 gene is almost ubiquitously expressed; therefore, it is remarkable that the main clinical 
manifestation associated with germline gain-of-function mutations in GNA11 is an abnormality in cal-
cium regulation. Studies in transfected cells show that the gain-of-function Gα11 mutations of  ADH2 
Figure 1. GNA11R6OC mutant increas-
es Ca2+i responses, which can be 
normalized by the calcilytic NPS 2143. 
(A) Immunofluorescent images of 
HEK-CASR cells transiently transfected 
with WT (Arg60) or mutant (Cys60) pBI-
CMV2-GNA11 constructs. All constructs 
had similar expression of GFP. Scale 
bars: 10μm. (B) Western blot analysis of 
lysates from HEK-CASR cells used for 
flow cytometry experiments. All cells 
expressed Gα11 and GFP at similar levels. 
Calnexin was used as a housekeeping 
protein. (C) Concentration-response 
curves showing normalized Ca2+i 
responses to increasing doses of [Ca2+]o 
in HEK-CASR cells expressing WT or 
GNA11R60C constructs. Mutant (Cys60) 
had a leftward shift in the concentra-
tion-response curve (blue, solid line, 
open circles) when compared with WT 
(Arg60; black, solid line, closed circles). 
Treatment of GNA11R60C expressing cells 
with increasing doses of the negative 
allosteric modulator NPS 2143 (red, 
dotted lines) led to a rightward shift 
in the dose response curves toward 
WT (Arg60) levels. (D) The GNA11R60C 
mutant (blue bar) was associated 
with reduced EC50 values compared 
with WT Gα11 (black bar). Treatment 
of GNA11R60C-expressing cells led to 
an increase in EC50 values, which was 
normalized to WT (Arg60) levels with a 
20 nM dose. (E) The GNA11R60C mutant 
(blue bar) and NPS 2143–treated cells 
had similar maximal responses (Emax) 
to WT (Arg60) cells. (F) The GNA11R60C 
mutant (blue bar) and NPS 2143–treat-
ed cells had similar Hill coefficient 
values to WT (Arg60) cells. Data is 
expressed as mean ± SEM. **P < 0.02. 
Experiments were performed in 4 inde-
pendent transfections.
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each result in a small but significant increase in the sensitivity with 
which the CASR responds to extracellular calcium, an effect that likely 
accounts for the perturbations in PTH secretion and calcium homeo-
stasis seen in patients (11–13). Short stature has been reported in affect-
ed individuals from two families (12, 14), suggesting possible effects 
on growth. The number of  reported patients with ADH2 is limited, 
however, such that additional disease phenotypes may exist. Further-
more, the best treatment options for patients with GNA11 mutations are 
still unclear. We therefore generated a knockin mouse model of  ADH2 
with a germline GNA11 c.C178T point mutation (p.Arg60Cys), which 
was identified in a family affected with ADH2 (10). We report here the 
phenotypic properties of  the mutant mice, as well as their response to 
treatment with two inhibitors with relevance to the disease; the small 
molecule calcilytic drug, NPS 2143, which acts as a negative allosteric 
modulator (NAM) of  the CASR and thereby can induce increased 
PTH secretion (20, 21); and the cyclic depsipeptide YM-254890, which 
acts as a competitive inhibitor of  Gα11/q (22–24).
Results
Effect of  the GNA11R6OC mutation on Ca2+i responses in vitro. To determine the effects of the Arg60Cys mutation 
on CASR-mediated signaling, WT HEK293 cells stably expressing the CASR (HEK-CASR) were transiently 
transfected with a pBI-CMV2 plasmid that encoded either the WT (Arg60) or mutant (Cys60) Gα11 protein. 
Expression levels of the CASR, Gα11, and GFP proteins were assessed by fluorescence microscopy and/or West-
ern blot analyses (Figure 1, A and B). Calnexin was used as a loading control in Western blot analyses, which 
showed similar expression levels for WT and mutant Gα11 proteins, both in the presence and absence of NPS 
2143 (Figure 1B). To assess function of the WT and mutant Gα11 proteins, we measured changes in intracellular 
calcium (Ca2+i) in response to alterations in extracellular calcium ([Ca
2+]o) by flow cytometry (11, 13). The Ca
2+
i 
responses in WT and mutant Gα11-expressing cells were shown to increase in a dose-dependent manner follow-
ing stimulation with increasing concentrations of Ca2+o, and the responses in the mutant GNA11
R6OC-expressing 
cells were significantly left-shifted as compared with those in the GNA11WT-expressing cells (Figure 1, C and 
D; EC50 = 2.91 mM [95% CI, 2.78–3.05 mM] for Arg60, compared with 3.60 mM [95% CI, 3.47–3.74 mM] 
for WT; P < 0.02), whereas the maximal signaling responses and Hill coefficients of WT and Cys60 mutant–
expressing cells were similar (Figure 1, E and F). These findings confirm that the GNA11R6OC mutant exerts a 
gain-of-function effect on CASR signaling and, thus, enhances the receptor’s sensitivity to Ca2+o (11–13).
Figure 2. Mutant mice with activating Gα11 have darker ear and tail color. (A and 
B) Increased tail and ear pigmentation of the mutant mice compared with WT 
littermates at age 12–13 weeks. Homozygous GNA11R6OC/R60C mice had darker color 
of their tails and ears than heterozygous GNA11R6OC/WT mice.
Figure 3. Knockin mice with activated Gα11 (GNA11R60C mutation) were hypocalcemic and hyperphosphatemic with inappropriately low parathyroid 
hormone (PTH) levels. Biochemical parameters of 9-week-old GNA11WT/WT mice (n = 26–28), GNA11R60C/WT heterozygous mice (n = 24), and GNA11R60C/R60C 
homozygous mice (n = 10). (A) Ionized calcium (iCa2+), (B) serum PTH, (C) serum phosphate (Pi) (*P < 0.05, **P < 0.01, ****P < 0.0001, using a one-way 
ANOVA test with Tukey’s multiple corrections). Data is reported as mean ± SD.
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Effect of  the calcilytic NPS 2143 on the gain-of-function associated with the GNA11R6OC mutation in vitro. To inves-
tigate whether allosteric inhibition of the CASR might rectify the gain-of-function effect imposed by the 
GNA11R6OC mutation, the effect of the NPS 2143 calcilytic compound on CASR signaling was examined in 
HEK-CASR cells expressing either WT Gα11 or mutant (Cys60) Gα11 proteins. NPS 2143 was used at 10, 20, 
and 30 nM concentrations, as similar doses of this calcilytic have been reported to rectify the altered signaling 
responses associated with different ADH2-causing Gα11 mutations (25) as assessed in similar cell-based assays 
(21). Consistent with these previous studies, NPS 2143 increased the EC50 of Gα11-Cys60–expressing mutant 
cells in a dose-dependent manner. Thus, 20 nM of NPS 2143 increased the EC50 of Cys60-expressing mutant 
cells from 2.91 mM (95% CI, 2.78–3.05 mM) in untreated cells to 3.76 mM (95% CI, 3.61–3.91 mM), which 
was not significantly different from the EC50 of 3.60 mM (95% CI, 3.47–3.74 mM) for WT cells; and 30 nM of  
NPS 2143 increased the EC50 of  the mutant cells to 4.56 mM (95% CI, 4.33–4.81 mM), which was significantly 
greater than that of WT cells (Figure 1, C and D). NPS 2143 had no effect on the maximal signaling responses 
or Hill coefficients of WT or mutant Gα11-expressing cells. Thus, the findings of these in vitro studies demon-
strate that NPS 2143 can rectify the gain-of-function effect associated with the GNA11R6OC mutation.
Phenotype of  GNA11R60C mice. Through CRISPR-Cas9 methodology, we successfully generated knockin 
mice with the GNA11R6OC mutation. Founder mice (8%) harbored the correct GNA11 c.C178T mutation 
generated by homology-directed repair. We confirmed by direct sequencing of  PCR products that F1 gen-
eration mice carried one GNA11R60C allele and one WT allele (data not shown). Three independent mouse 
lines gave indistinguishable results (data not shown). Intercrossing GNA11R60C heterozygous F1 mice yield-
ed a slightly lower number of  heterozygous and homozygous mice as compared with WT mice at the time 
of  weaning than would be expected by Mendelian genetics (Table 1).
Increased pigmentation of  tails and ears was noted in GNA11R60C mutant adult mice with an apparent 
gene-dosage effect (Figure 2). Body length and weight were similar between 13-week-old mutant mice and 
their same-sex WT littermates.
Homozygous and heterozygous mice had significantly lower serum ionized calcium (iCa2+) compared 
with age-matched WT animals (1.12 ± 0.05 mmol/l vs. 1.20 ± 0.04 mmol/l vs. 1.25 ± 0.03 mmol/l; mean 
± SD; P < 0.0001; Figure 3). PTH levels (mean ± SD) were similar in both the heterozygous (146 ± 159 pg/
ml) and homozygous mice (119 ± 129 pg/ml) as compared with WT mice (211 ± 221 pg/ml) and therefore 
Figure 4. Mutant mice have reduced 
bone mineral density and bone 
volume fraction. μCT analysis 
revealed significant decreases in 
bone mineral density (BMD) (A) and 
bone volume fraction (BV/TV) (B) in 
12- to 13-week-old male GNA11R60C/WT 
(n = 7) vs. GNA11WT/WT (n = 6); female 
GNA11R60C/WT (n = 5) vs. GNA11WT/WT (n 
= 6), and female GNA11R60C/R60C (n = 
3) vs. GNA11WT/WT (n = 6) mice. Data 
are shown as mean ± SD. Only 1 male 
GNA11R60C/R60C survived to μCT analysis. 
This mouse showed a BMD of 185 
mgHA/cm3 and BV/TV of 16.33% (Sup-
plemental Figure 1). The 3 groups of 
female mice were analyzed by ANOVA 
with Tukey’s multiple comparisons 
tests, and the 2 groups of male mice 
were analyzed by Student’s t test. (*P 
< 0.05, **P < 0.01, ***P < 0.005). (C) 
μCT image of the distal femur of rep-
resentative 12-week-old female mice. 
Scale bar: 1 mm.
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inappropriate, given the degree of  hypocalcemia. As frequently found in hypoparathyroid patients, serum 
phosphate was significantly higher in the homozygous GNA11R60C/R60C mice (7.19 ± 1.11 mg/dl) as compared 
with either WT (5.90 ± 1.24 mg/dl) or heterozygous GNA11R60C/WT mice (6.33 ± 1.02 mg/dl) (mean ± SD).
μCT analysis revealed significantly lower bone mineral density (BMD) and bone volume/total volume 
(BV/TV) in both female (heterozygous and homozygous) and male (heterozygous) mice compared with 
WT mice at age 12–13 weeks (Figure 4 and Table 2). Only 1 male GNA11R60C/R60C mouse was available 
for μCT analysis at age 12–13 weeks, but at age 20 weeks, male homozygous mice had a significantly 
lower BMD and BV/TV as compared with WT mice (Supplemental Figure 1; supplemental material avail-
able online with this article; http://doi.org/10.1172/jci.insight.91079DS1). In 12- to 13-week-old female 
mutant mice, the trabecular number (Tb.N) was decreased and trabecular spacing (Tb.Sp) increased in a 
gene dosage–dependent pattern. Compared with WT mice, cortical thickness (Ct.Th) was also significantly 
decreased in the female mutant mice (Table 2). Whole-body and hind limb BMD of  12-week-old mice 
measured by dual-energy X-ray absorptiometry (DXA) was significantly lower in female heterozygous and 
homozygous compared with WT mice (Supplemental Figure 2), but in male mice, differences did not reach 
significance (Supplemental Figure 2).
There was no significant difference in fasting spot urinary fractional excretion index of  calcium (FEICa) 
(Figure 5) or urinary calcium/creatinine ratio (Supplemental Figure 3) between any of  the groups.
Treatment of  mice with the calcilytic NPS 2143. Four hours after i.p. injection of  NPS 2143, serum ion-
ized calcium and PTH concentration significantly increased in WT, GNA11R60C/WT, and GNA11R60C/R60C 
mice compared with their respective baseline levels and compared with vehicle-treated controls (Figure 
6 and Supplemental Table 1). Twenty-four hours after the injection, the ionized calcium level of  the WT 
mice treated with the calcilytic was still elevated compared with vehicle (P = 0.02), but there was no lon-
ger a difference between the calcilytic and vehicle groups in the mutant animals. Serum phosphate levels 
increased significantly in WT mice 4 hours after treatment with NPS 2143 but not in the NPS 2143–treated 
GNA11R60C/WT or GNA11R60C/R60C mice. The fasting spot urinary FEICa was significantly decreased in the 
GNA11R60C/WT and GNA11R60C/R60C mice at 4 hours after treatment with the calcilytic (Figure 5). There was 
no change in the urinary calcium/creatinine ratio between any of  the groups (Supplemental Figure 3).
Treatment of  mice with the Gα11/q inhibitor YM-254890. Four hours after single-dose i.p. injection of  
YM-254890, there was a significant 
increase in the serum ionized calcium 
concentration in the WT mice (Figure 7, 
A–C, and Supplemental Table 2). Hetero-
zygous GNA11R60C/WT mice treated with 
YM-254890 also had an increase in cal-
Table 1. Observed vs. expected number (percentage) of GNA11WT/WT, GNA11R60C/WT heterozygous, and GNA11R60C/R60C homozygous animals 
from heterozygous matings at the time of weaning. 
GNA11R60C/WT × GNA11R60C/WT WT GNA11R60C/WT GNA11R60C/R60C
Expected Mice 15 (25%) 30 (50%) 15 (25%)
Viable Mice 24 (40%) 26 (43%) 10 (17%)
The observed distribution differed from the expected (25% WT, 50% heterozygous, 25% homozygous) (χ2 statistic 7.6, 2 degrees of freedom, P = 0.022).
 
Figure 5. Decrease in the fractional excretion index of calcium after treatment 
of mice with a single injection of a calcilytic. Fractional excretion of calcium was 
determined in WT (GNA11WT/WT, n = 28 baseline, n = 14 vehicle, n = 9 calcilytic), 
heterozygous (GNA11R60C/WT, n = 21 baseline, n = 13 vehicle, n = 10 calcilytic), or 
homozygous mice (GNA11R60C/R60C, n = 9 baseline, n = 5 vehicle, n = 5 calcilytic) at 
baseline and 4 hours after bolus i.p. injection of either vehicle (Veh) or 28 mg/
kg of the calcilytic NPS 2143 (Drug). Data are shown as mean ± SD. At baseline, 
results for the 3 genotypes were analyzed using one-way ANOVA with Tukey’s 
multiple corrections. At 4 hours, vehicle- and calcilytic-treated groups were com-
pared by Student’s t test. (*P < 0.05, **P < 0.01).
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cium as compared with vehicle-treated mice, but the effect did not quite reach statistical significance (P 
= 0.06). The homozygous GNA11R60C/R60C mice exhibited no change in blood ionized calcium concentra-
tion in response to YM-254890 treatment. Mean PTH levels increased significantly in the WT mice after 
injection of  YM-254890, but individual levels varied and some mice had no increase in PTH. YM-254890 
induced no significant change in PTH levels in the heterozygous or homozygous mice (Figure 7, D–F). Lev-
els of  serum phosphate and urinary fractional excretion of  calcium were unchanged in any of  the groups 
at 4 hours after treatment with YM-254890 as compared with treatment with vehicle (Figure 7, G–I, and 
Supplemental Table 2).
Inhibition of  iCa2+ signaling through Gα11/q in vitro using YM-254890. Consistent with the lack of  efficacy 
of  the Gα11/q inhibitor in mice homozygous for GNA11
R6OC, in vitro studies showed that YM-254890 had 
no effect on Ca2+i signaling mediated by another GPCR, the PTH1R, in HEK-293–derived cells expressing 
GNA11R6OC (Figure 8). The PTH1R was used for this in vitro analysis, as we found it to give more robust 
agonist-induced Ca2+i responses than the CASR or the endogenous P2Y1 purinergic receptors stimulated 
with [Ca2+]o and ADP, respectively, and thus could better reveal effects of  the inhibitor compound (data not 
shown). When GNA11WT was introduced into HEK cells lacking functional Gα11/q, PTH-induced stimula-
tion of  Ca2+i signaling via the PTH1-receptor in HEK cells was fully inhibited by YM-254890.
Discussion
This study reports the generation, through CRISPR-Cas9 technology, of  a mouse model of  ADH2 harbor-
ing a knockin of  the activating mutation GNA11R6OC, discovered in a family with the disease (10). These 
mice faithfully replicate ADH2 and enable a more in-depth analysis of  the effects of  the GNA11R6OC muta-
tion on tissue-specific phenotypes, as well as the potential for selected inhibitor compounds to modify or 
correct the ADH2 phenotype. Our in vitro studies with HEK cells stably expressing the CASR confirmed 
that GNA11R6OC exerts a gain-of-function effect on CASR signaling, in that the mutant protein caused a 
leftward shift in the calcium dose–response curve, indicating an increased sensitivity to [Ca2+]o. This gain-
of-function effect of  the Gα11 mutant on CASR signaling is consistent with the effects observed for other 
Gα11 mutations identified in ADH2 and, mechanistically, can explain the hypocalcemic and hyperphospha-
temic disturbances seen in ADH2 patients (10–14), which are fully recapitulated in the GNA11R60C mutant 
mice. The results, thus, establish that the mutation is sufficient to cause ADH2 and provide a plausible 
mechanistic basis of  the disease.
ADH2 in humans follows a heterozygous, autosomal-dominant mode of  inheritance. Compared with 
heterozygous mice, homozygous ADH2 mice showed more severe abnormalities in all parameters mea-
sured. Thus, there was a clear gene-dosage effect of  the Arg60Cys mutation on the calcium, phosphate, 
and bone homeostasis. In 3 independent breeding lines, we observed a lower-than-expected proportion of  
viable animals with the ADH2 mutation. This suggests a possible survival disadvantage conferred by the 
mutation. In humans, highly activating gain-of-function Gα mutations are only encountered as somatic 
mutations, often in tumors, and are not transmitted through the germline. Interestingly, a transgenic mouse 
with a heritable Gαs
R201C mutation has been described (26). Compared with such oncogenic mutations, 
which affect residues Arg183 and Gln209 (Gα11/q nomenclature) that are directly involved in GTP catalysis, 
Table 2. Bone mineral density (BMD) and trabecular and cortical microarchitecture at 12–13 weeks of age in WT GNA11WT/WT, 
heterozygous GNA11R60C/WT, or homozygous GNA11R60C/R60C mutant mice. 
BMD (mgHA/cm3) BV/TV (%) Tb.N (1/mm) Tb. Th (mm) Ct.Th (mm) Ct.Ar (mm2) Tt.Ar (mm2)
Female WT (n = 6) 140 ± 12 AB 10.55 ± 1.78AB 3.587 ± 0.305AB 0.051 ± 0.003 0.150 ± 0.009AB 0.628 ± 0.041B 1.624 ± 0.067
 GNA11R60C/WT (n = 5) 112 ± 12A 7.45 ± 1.47A 2.815 ± 0.596AC 0.050 ± 0.003 0.136 ± 0.006A 0.567 ± 0.052 1.569 ± 0.146
 GNA11R60C/R60C (n = 3) 101 ± 11B 5.31 ± 1.33B 1.879 ± 0.402BC 0.051 ± 0.003 0.131 ± 0.004B 0.533 ± 0.031B 1.503 ± 0.136
Male WT (n = 6) 191 ± 32A 17.34 ± 4.19A 4.821 ± 0.353 0.056 ± 0.010 0.151 ± 0.008 0.675 ± 0.055 1.765 ± 0.078
 GNA11R60C/WT (n = 7) 159 ± 8A 13.12 ± 1.16A 4.504 ± 0.290 0.049 ± 0.003 0.147 ± 0.009 0.643 ± 0.029 1.705 ± 0.052
 GNA11R60C/R60C (n = 1) 185 16.33 4.78 0.05 0.152 0.598 1.460
Bone parameters as reported from μCT analysis of WT, heterozygous, and homozygous GNA11R60C/R60C mice. All statistics were by ANOVA with Tukey’s 
multiple comparisons tests. (AP < 0.05 WT vs. heterozygous; BP < 0.05 WT vs. homozygous; CP < 0.05 heterozygous vs. homozygous). BV/TV, bone volume/
total volume; Tb.N, trabecular network; Tb.Th, trabecular thickness; Ct.Th, cortical thickness; Ct.Ar, cortical area; Tt.Ar, total cross-sectional area. 
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the gain-of-function Gα11 mutations of  ADH2 — which affect residues more distant from the GTPase site 
(Figure 8D) — appear to have milder effects on G protein function (12); this may explain why these muta-
tions are sufficiently tolerated to allow germline transmission.
Hypercalciuria and the attendant risk of  nephrocalcinosis are potential complications for patients 
with ADH1, in which the combined effects of  enhanced CASR signaling in the parathyroid glands and 
in the renal distal tubules can result in marked increases in calcium excretion (19, 27). In principle, ADH2 
patients would also be expected to exhibit elevated levels of  calcium excretion, but data are limited and 
variable (10–14). In our estimates of  urinary fractional excretion of  calcium, we detected no difference 
between WT and the hypocalcemic heterozygous and homozygous mutant ADH2 mice at baseline while 
fasting. There was also no difference in the spot urine calcium/creatinine ratio between the groups of  ani-
mals. While the lack of  difference in fractional excretion of  calcium at baseline in a steady state could indi-
cate that the activated Gα11 mutant does not have a dominant effect on CASR function in the renal distal 
tubule cells, more extensive analyses — for example, involving 24-hour urine collections — are needed to 
resolve such potential effects of  the mutation on renal function. In any case, it is clear that the mutant Gα11 
impacted CASR signaling in the parathyroid glands, as the ADH2 mice were significantly hypocalcemic 
with reduced or inappropriately normal serum PTH levels.
The hypocalcemic phenotype of  patients and animals with ADH2 is best explained by the effects of  
gain-of-function Gα11mutations on signaling through the CASR receptor. In this model, the mutant Gα11 
leads to increased intracellular signaling when the CASR is activated by [Ca2+]o. The effects of  the mutant 
Gα11 would, thus, overlap with those caused by activating mutations in the CASR. Given that Gα11 can likely 
Figure 6. Calcium and parathyroid hormone (PTH) increased significantly after injection of the calcilytic in WT mice and mice 
with activating Gα11. (A–C) Biochemical parameters at baseline and 4 and 24 hours after bolus i.p. injection of the calcilytic NPS 
2143 (Drug) at 28 mg/kg or vehicle (Veh) in 9-week-old GNA11WT/WT (n = 14 vehicle, n = 14 calcilytic), GNA11R60C/WT (n = 13 vehicle,  
n = 13 calcilytic), and GNA11R60C/R60C (n = 6 vehicle, n = 6 calcilytic) mice. (A–C) blood iCa2+, (D–F) serum PTH, (G–I) serum Pi. Data 
are shown as mean ± SD. (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, using Student’s t test).
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couple to a number of  other GPCRs, it seems rather surprising that ADH2 patients do not show broader 
effects of  the mutation beyond calcium homeostasis. We did, however, observe several additional pheno-
typic traits in the ADH2 mutant mice, including darker skin coloration readily visible on the tail and ears. 
This trait closely matches that seen in the “dark skin” mouse strain, Dsk7, which also harbors a moderately 
activating mutation (Ile62Val, previously listed as Ile63Val) in Gα11; in this case, the endothelin receptor B 
(ENDR-B) was suggested as a key codeterminant of  the increased skin pigmentation (28). While no patient 
with a Gα11 gain-of-function mutation has yet been reported to have increased skin pigmentation, our data 
suggest that, in mice, the human GNA11R6OC mutant of  ADH2 can alter at least some GPCR signaling path-
ways other than the CASR, including those probably involving ENDR-B.
The decreased BMD in the mutant ADH2 mice is also of  interest. This finding is notably different from 
the increased BMD typically present in patients with other forms of  hypoparathyroidism (29, 30). It is also 
different from the findings of  increased BMD in knockin mice expressing an activated CASR mutant (31). 
By contrast, transgenic mice expressing an oncogenic variant of  the closely related Gαq (Gαq
Q207L) in osteo-
blasts through the col. 1 promoter have osteoporosis (32), and related studies in vitro show that activation 
of  Gαq signaling inhibits osteoblast differentiation (32). Thus, it is plausible that the GNA11
R6OC mutant 
Figure 7. Treatment of mice with single bolus injection of Gα11/q inhibitor (YM-254890). iCa2+ and parathyroid hormone (PTH) increased in WT and hetero-
zygous GNA11R60C/WT but not homozygous GNA11R60C/R60C mice. Biochemical parameters at baseline and 4 hours after bolus i.p. injection of YM-254890 at 0.15 
mg/kg or vehicle in 12-week-old GNA11WT/WT (n = 11 vehicle, n = 11 YM-254890), GNA11R60C/WT (n = 12 vehicle, n = 12 YM-254890), and GNA11R60C/R60C (n = 5 vehicle, 
n = 5 YM-254890) mice. (A–C) blood iCa2+, (D–F) serum PTH, (G–I) serum Pi. Data are shown as mean ± SD (*P < 0.05, ***P < 0.001, using Student’s t test).
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leads to low BMD through direct effects on osteoblasts. The mediators of  such an effect, upstream or down-
stream of  the mutant Gα11, are unclear. Although short stature was reported in 2 families with ADH2 (12, 
14), we did not detect a difference in weight or length between the mutant ADH2 mice and WT controls. 
Future experiments are necessary to define the full spectrum of  effects of  this gain-of-function mutation in 
Gα11 on various GPCR-controlled signaling responses in different tissues. 
In theory, gain-of-function Gα11 mutants could either lead to enhanced downstream signaling indepen-
dent of  any upstream GPCR — as is seen with highly activating, oncogenic mutations — or increased signal-
ing initiated by an activated GPCR. Our in vitro studies, measuring changes in Ca2+i as a measure of  signaling 
via the IP3/PLC/Ca
2+
i pathway detected an enhancement in CASR-mediated signaling in HEK-293–derived 
cells expressing the CASR and the GNA11R6OC mutant. Babinsky et al. demonstrated similar enhancements in 
CASR signaling responsiveness with other Gα11 gain-of-function variants — Gα11
R181Q and Gα11
F341L — found 
in ADH2 (25). The calcilytic NPS 2143, a NAM of CASR function, was shown to suppress the enhancing 
effects of  the Gα11
R181Q and Gα11
F341L mutants on CASR signaling in cell-based assays (25). Likewise, we test-
ed the same NAM on the GNA11R6OC mutation and found that it could shift the calcium response curve to 
match that obtained with WT Gα11. Moreover, NPS 2143 could partially rescue the calcium-homeostatic 
defects induced by these mutant Gα11 proteins in mice. These findings suggest that further exploration of  such 
CaSR-targeted inhibitor compounds might be a viable path toward new therapeutic strategies for ADH2. A 
potential benefit suggested by our current studies in the ADH2 mice (Figure 5) is that such a CASR-specific 
NAM could help reduce urinary calcium excretion by not only raising serum PTH via effects on the parathy-
roid glands, but also by having direct effects on CASR function in the distal tubule. The apparent lack of  a 
Figure 8. YM-254890 fully inhibited parathyroid hormone–induced (PTH-induced) stimulation of Ca2+i signaling via the PTH1 
receptor in HEK cells transfected with GNA11WT but not with GNA11R6OC. Fura-2–treated HEK-293–derived cells in which the genes 
encoding the endogenous Gαq and Gα11 were knocked out were cotransfected with plasmids encoding either Gα11
R60C (A) or Gα11WT (B), 
along with the PTHR1. Forty-eight hours after transfection, cells were pretreated for 45 minutes with Fura-2,AM at a concentration 
of 5 × 10–6 M, together with either DMSO (0.1%) or DMSO containing YM-254890 at the indicated concentration and then treated 
with vehicle (Veh.) or PTH(1-34) (1 × 10–7 M) and analyzed for changes in Ca2+i signaling: blue line, PTH + DMSO; green line, PTH + 1 
× 10-8 M YM-254890; red line, PTH + 1 × 10-7 M YM-254890; purple line, PTH + 1 × 10–6 M YM-254890; orange line, PTH + 1 × 10–5 M 
YM-254890; aqua line, PTH + 1 × 10–4.5 M YM-254890; black line, Vehicle + DMSO. Ratiometric Fura-2 fluorescence was measured 
using an Envision plate reader. Data are means (± SEM) of duplicate wells from a single experiment; 2 other replicate experi-
ments yielded comparable results. (C) Dose-response curves for YM-254890 generated by plotting the AUC for each PTH-induced 
response observed in the absence or presence of inhibitor in the experiments of panels A and B. (D) Model of Gαq in complex with 
YM-254890. The orientation on the left shows the close proximity of Arg60, mutated in ADH2, with YM-254890 (red), and the 
orientation on the right shows the close proximity of Arg183, at which more strongly activating oncogenic mutations occur, with 
bound guanine nucleotide GDP (cyan). The side chain nitrogens of Arg60 and Arg180 are colored blue; the RAS and helical portions 
of the G protein are shaded dark and light gray, respectively, and helix-5 of the RAS domain, which participates in GPCR interaction, 
is shaded aqua. The model was prepared using the x-ray coordinate file PDB.3AH8 (23).
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reduction in urinary fractional excretion of  calcium by NPS 2143 in our WT mice is likely due, in part, to the 
limitations of  our FEICa data, as only a single spot urine sample was collected and analyzed. The analysis 
of  renal calcium handling in ADH2 is also complicated by the possibility that Gα11 could couple to both the 
CASR and to the PTH receptor (PTH1R), which mediate opposing effects on renal calcium transport. Thus, 
more extensive studies on the renal handling of  calcium and other mineral ions (e.g., sodium, phosphate, and 
magnesium), as well as on GFR and serum FGF23 levels, are needed to fully define the role of  Gα11 function 
in the kidney. The fact that the serum phosphate concentration increased in WT mice after calcilytic treatment 
— rather than decreased, as might be expected from the elevations in PTH — could be explained by excessive 
PTH-induced bone resorption, as the phosphate mobilized from the mineral matrix would exceed the short-
term phosphate-excretion capacity of  the kidney.
Overall, the response of  the GNA11R60C mice to treatment with a calcilytic is of  considerable inter-
est, as it suggests that the gain-of-function effect of  the Arg60Cys mutation, which maps to helix-1 of  
the G protein, is at least partly dependent on coupling to the CASR. These findings are particularly 
interesting in the light of  data from a recent Phase II clinical trial, which shows promise for calcilytics 
in patients with ADH1 (33). Our study supports the further exploration of  these compounds for use in 
patients with ADH2.
Given that ADH2 arises from mutations in Gα11, we explored the potential efficacy of  a specif-
ic Gα11/q inhibitor, YM-254890, to correct the defects in calcium homeostasis in the ADH2 mice. 
YM-254890 is a cyclic depsipeptide that binds specifically to Gα11 and Gαq and inhibits GDP release 
and hence activation of  these two G proteins (23). It is a natural product that was first isolated from 
the bacterium Chromobacterium sp. as an inhibitor of  ADP-induced platelet aggregation (22). Successful 
total synthesis has recently been reported (24). X-ray crystallography has shown that YM-254890 bound 
to Gαq, which is very similar to Gα11, interacts with switch 1 and hinders linker flexibility between the 
GTPase domain and the helical domain of  the Gα11/q protein (Figure 8D). The decreased flexibili-
ty stabilizes the Gα11/q protein in the GDP-bound inactive state, therefore inhibiting Gα11/q activation 
(23). Our studies show for the first time to our knowledge that inhibition of  Gα11/q in WT mice by this 
compound significantly increases blood calcium levels, presumably by increasing secretion of  PTH. 
These observations also suggest that a low basal-state level of  Gα11 signaling in the parathyroid glands, 
induced by normal ambient blood calcium levels, acts to maintain a tonic suppression of  PTH secre-
tion. Treatment with the Gα11/q inhibitor releases this tonic suppression and increases PTH release. The 
published crystal structure of  YM-254890 in complex with the related Gαq also revealed that the com-
pound forms a key hydrogen bond with Arg60 of  the G protein (23). The replacement of  this Arg60 by 
cysteine, as in the mutant studied here, is therefore predicted to render the mutant G protein resistant 
to the inhibitory effect of  YM-254890. The compound indeed showed lack of  efficacy in homozygous 
mutant mice, confirming a critical role for the Arg60 residue in binding YM-254890 to Gα11. We did, 
however, observe rescue effects of  the compound in heterozygous mice as nonsignificant increases in 
PTH and calcium levels, which are likely due to the presence of  the one WT Gα11 allele. We conclude 
that the inhibitor requires the presence of  at least one WT Gα11 allele to function in the context of  this 
particular ADH2 mutation.
The different effects of  YM-254890 on WT vs. mutant Gα11 in vivo are also consistent with our in vitro 
studies. We showed that YM-254890 failed to inhibit Ca2+i signaling through the mutated Gα11
R6OC, but it 
did inhibit signaling through the WT Gα11. This supports the notion that the YM-254890 class of  com-
pounds should be further explored for therapeutic potential in the heterozygous disease ADH2, irrespective 
of  the predicted sensitivity of  the mutated allele to YM-254890.
In summary, we used CRISPR-Cas9 technology to create a mouse model of  ADH2 harboring an acti-
vating mutation in GNA11. The GNA11R60C mutant knockin mice mimic the human disease, with hypocalce-
mia and inappropriately low PTH levels demonstrating that this mutation is sufficient to cause ADH2. We 
also observed additional pathologies that have so far not been reported for ADH2 — namely increased skin 
pigmentation and low bone mineral density. Thus, this mouse model gives clues as to additional defects 
that might arise in patients with such an activating mutation in Gα11.
We further show that the activity of  the mutant G protein is at least partly dependent on coupling 
to the CASR and is, thus, quite distinct from the activity associated with the more widely known G pro-
tein activating mutations (e.g., GαS
R201H found in McCune Albright Syndrome that directly affects the 
GTPase site, resulting in stronger, often oncogenic signaling effects that are not observed as inheritable 
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germline mutations). Treatment with the CASR-targeted calcilytic NPS 2143 effectively increased 
serum calcium and PTH levels in the mutant GNA11R60C mice, suggesting its potential for treatment of  
ADH2. The specific Gα11/q inhibitor, YM-254890, was without efficacy in homozygous mice, reflecting 
the requirement for Arg60 in binding the drug; however, it increased serum calcium and PTH in het-
erozygous mice, and thus may be an alternative approach to therapy of  ADH2 as well as other diseases 
involving alterations in Gαq or Gα11 signaling.
Methods
Compounds. NPS 2143 hydrochloride (2-Chloro-6-[(2R)-3-[[1,1-dimethyl-2-(2-naphthalenyl)ethyl] 
amino]-2-hydroxypropoxy]-benzonitrile hydrochloride) was obtained from Sigma-Aldrich (catalog 
SML0362) and dissolved in a 20% aqueous solution of  2-hydroxypropyl-β-cyclodextrin (Sigma-Aldrich, 
catalog H107) prior to use in in vitro studies, as described (21, 25). YM-254890 was synthesized as 
previously described (24).
Cell culture and transfection. Functional studies were undertaken using a human GNA11 construct (11), 
as the human and mouse Gα11 proteins share an overall amino acid identity of  98% and are 100% identical 
in the region surrounding the mutated site. WT and mutant pBI-CMV2-GNA11 expression constructs were 
generated as described (11). Site-directed mutagenesis was used to generate the mutant GNA11 construct 
using the Quikchange Lightning Site-directed Mutagenesis kit (Agilent Technologies) and gene-specific 
primers (Sigma-Aldrich), as described (34). This bidirectional pBI-CMV2 vector allows for coexpression 
of  Gα11 and GFP at equivalent levels (11). Constructs were transiently transfected into HEK293 cells 
stably expressing CASR (HEK-CASR) using Lipofectamine 2000 (Invitrogen). Cells were maintained in 
DMEM-Glutamax media (Thermo Fisher Scientific) with 10% FBS (Gibco) and 400 μg/ml geneticin 
(Thermo Fisher Scientific) at 37°C, 5% CO2. Successful transfection was confirmed by visualizing GFP 
fluorescence using an Eclipse E400 fluorescence microscope with a Y-FL Epifluorescence attachment and 
a triband 4,6-diamidino-2-phenylindole-FITC-Rhodamine filter, and images captured using a DXM1200C 
digital camera and NIS Elements software (Nikon) (11, 35). The expression of  Gα11 and CASR proteins 
was also determined by Western blot analysis using anti-Gα11 (Santa Cruz Biotechnology Inc., sc-390382), 
anti-GFP (Santa Cruz Biotechnology Inc., sc-9996), anti-calnexin (Millipore, AB2301), or anti-CASR 
(AbCam, ab19347) antibodies. The Western blots were visualized using an Immuno-Star WesternC kit 
(Bio-Rad) on a Bio-Rad Chemidoc XRS+ system (11).
Ca2+i measurements. The Ca
2+
i responses of  HEK293-CASR cells expressing WT or mutant Gα11 pro-
teins were assessed by a flow cytometry-based assay, as described (11, 35). In brief, HEK293-CASR cells 
were cultured in T75 flasks and transiently transfected 24 hours later with 16 μg DNA (11). Forty-eight 
hours following transfection, the cells were detached, resuspended in calcium-free (Ca2+-free) and magne-
sium-free (Mg2+-free) HBSS, and loaded with 1 μg/ml Indo-1-acetoxymethylester (Indo-1-AM, Molecular 
Probes) for 1 hour at 37°C. After removal of  free dye, cells were resuspended in Ca2+- and Mg2+-free HBSS 
and maintained at 37°C. Transfected HEK-CASR cells were incubated with either a 20% aqueous solution 
of  2-hydoxypropyl-β-cyclodextrin (Sigma-Aldrich) (vehicle) or NAM NPS 2143 (Sigma-Aldrich) at con-
centrations of  10, 20, and 30 nM for 1 hour, as previously described (25). Transfected cells, in suspension, 
were stimulated by sequentially adding Ca2+ to the Ca2+- and Mg2+-free HBSS to increase the [Ca2+]o in 
a stepwise manner from 0–15 mM, and then analyzed on a MoFlo modular flow cytometer (Beckman 
Coulter) by simultaneous measurements of  GFP expression (at 525 nm), Ca2+i-bound Indo-1AM (at 410 
nm), and free Indo-1AM (i.e., not bound to Ca2+i) (at 485 nm), using a JDSU Xcyte UV laser (Coherent 
Radiation) on each cell at each [Ca2+]o, as described (11, 35). The peak mean fluorescence ratio of  the 
Ca2+i transient response after each individual stimulus was measured using Cytomation Summit software 
(Beckman Coulter) and expressed as a normalized response, as described (11, 35). Nonlinear regression 
of  concentration-response curves was performed with GraphPad Prism using the normalized response at 
each [Ca2+]o for each separate experiment for the determination of  EC50 (i.e., [Ca
2+]o required for 50% of  
the maximal response) and Hill coefficient values (36). The maximal signaling response was measured as a 
fold-change of  the peak transient Ca2+i response to the basal Ca
2+
i response measured at 0 mM [Ca
2+]o (36). 
The maximal signaling responses for mutant Gα11 proteins were expressed as a percentage of  the WT Gα11 
protein maximal signaling response. The mean EC50 and Hill coefficients obtained from 4 separate trans-
fection experiments were used for statistical comparison by using the F-test, and alterations in maximal 
signaling responses assessed using the Mann-Whitney U test (36).
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Ca2+ signaling and YM-254890. The effects of  the Gα11/q specific inhibitor, YM-254890 (24, 37), on the 
PLC/IP3/iCa
2+ signaling capacities of  GNA11R6OC and GNA11WT were analyzed utilizing Fura-2–treated 
HEK-293–derived cells in which the genes encoding the endogenous Gαq and Gα11 were knocked out (37). 
The cells were seeded in black 96-well plates and cotransfected using Lipofectamine 2000 (Thermo Fisher 
Scientific) with plasmids encoding either GNA11R6OC or GNA11WT, along with the PTHR1. The PTHR1 
was chosen as a GPCR because it gives robust iCa2+ signaling responses in this assay format. The cells were 
analyzed 48 hours after transfection for PTH-induced Ca2+i signaling. The cells were, thus, pretreated for 45 
minutes with media containing 5 μM Fura-2,AM (Invitrogen, f1221), with or without YM-254890 (30 μM 
to 10 nM); the cells were then rinsed and base-line ratiometric fluorescence (λ excitation 340 nm and 380 
nm, λ emission, 515 nm) was measured using an Envision plate reader (PerkinElmer) for 14 seconds; the 
cells were then treated with hPTH(1-34) (100 nM), and measurements were continued for an additional 120 
seconds. Dose-response curves for YM-254890 were generated by plotting the AUC for each PTH-induced 
response observed in the absence or presence of  inhibitor.
CRISPR/Cas9 generation of  GNA11R60C mice. Mice with the point mutation c.C178T (p.Arg60Cys) in 
GNA11, the gene encoding Gα11, were generated by homology-directed repair using the CRISPR-Cas9 sys-
tem. Single-guide RNAs (sgRNAs) targeting the region around the genomic sequence that codes for Arg60 
were designed (http://crispr.mit.edu) and cloned into the pSpCas9n(BB)-2A-GFP plasmid (Addgene) (38). 
The efficacy of  different sgRNA to create double-stranded DNA breaks was estimated by determining the 
frequency of  mutations that were created in vitro in C3HT10½ cells using the TIDE algorithm (39). The 
sgRNA with the best efficiency in vitro, CCTCCGAGTAGCCGGCCCCG, was found to induce a DNA 
break in 67% of  the sequences and was therefore selected for zygote injection. In vitro transcription of  the 
guide RNA was performed as described by Yang et al. (40).
A single-strand DNA oligonucleotide template of  150 bp that contained the GNA11 c.C178T mutation 
(p.Arg60Cys) and homology arms of  56 bp and 57 bp was synthesized. Nine other silent bp changes were 
incorporated to avoid guide recognition of  the oligonucleotide template and to create a ScaI restriction site 
if  the homology-directed repair was successful.
C57BL/6 mice zygotes (Charles River Laboratories) were injected with synthetic Cas9 RNA (System 
Biosciences Inc.), the purified sgRNA, and the oligonucleotide DNA template. The zygotes were implanted 
into 11 recipient dams.
Mice were housed in the Center for Comparative Medicine (CCM) at Massachusetts General Hospital 
(MGH) in conditions of  23°C with 40% humidity in a 12-hour light/dark cycle with wood bedding and 
igloo covers. Mice had free access to water and irradiated diet (when not fasting) consisting of  1.11% calci-
um, 0.48% phosphate, and 2.5 IU/g vitamin D. The mutant mice did not require a rescue diet.
Characterization of  GNA11R60C mice. Founder mice were identified by isolating tail DNA and cloning 
the GNA11R60 region into single clones, which were then sequenced. Founder mice were crossed with WT 
C57BL6 mice to generate the heterozygous F1 generation, which were crossed to yield the experimen-
tal animals. Male and female mice from 3 independent breeding lines were included in the experimen-
tal group. Genotyping for the presence of  the Arg60Cys allele was performed by isolation of  genomic 
DNA from mouse tail and PCR-amplification using primers 5’-CACAGTAGGTGGGCAGGACT-3’ and 
5’-GCCTCAAGGGCAGATACCTT-3’. The 325 bp PCR product was digested with ScaI to survey for the 
mutant allele.
At age 12–13 weeks, mice were sacrificed and their weight and length measured. In vivo measurements 
of  whole-body (excluding the head) or hind limb BMD (g/cm2) were obtained at time of  sacrifice using 
peripheral DXA (PIXImus II, GE Lunar Corporation), as previously described (41).
μCT imaging was performed on the femurs of  female and male mice. A high-resolution desktop 
micro-tomographic imaging system (μCT40, Scanco Medical AG) was used to assess bone mineral densi-
ty, trabecular bone microarchitecture, and cortical bone morphology in the distal femoral metaphysis and 
mid-diaphysis. Scans were acquired using a 10 μm3 isotropic voxel size at 70 kVP, 114 mAs, 200 ms inte-
gration time, and were subjected to Gaussian filtration and segmentation. Image acquisition and analysis 
protocols adhered to the Journal of  Bone and Mineral Research (JBMR) guidelines (42). Trabecular bone 
was evaluated in a 1,500 μm (150 transverse slices) region beginning 200 μm above the peak of  the distal 
growth plate and extending proximally. Trabecular bone was segmented from soft tissue using a threshold 
of  314 mgHA/cm3, and the Scanco Evaluation program trabecular morphology script was used to mea-
sure bone volume fraction (BV/TV, %), trabecular thickness (Tb.Th, mm), Tb.N (1/mm), Tb.Sp (mm), 
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and trabecular BMD (Tb. BMD, mgHA/cm3). Cortical bone was evaluated in a 500-μm long (50 trans-
verse slices) at the femoral mid-diaphysis. Cortical bone was segmented using a threshold of  700 mgHA/
cm3 and then evaluated using the Scanco mid-shaft evaluation script to measure total cross-sectional area 
(Tt.Ar, mm2), cortical bone area (Ct.Ar, mm2), medullary area (Ma.Ar, mm2), bone area fraction (Ct.Ar/
Tt.Ar, %), cortical tissue mineral density (Ct.TMD, mgHA/cm3), Ct.Th (mm), and cortical porosity (%), 
as well as maximum, minimum, and polar moments of  inertia (Imax, Imin, and J, mm4).
Treatment of  mice with the calcilytic NPS 2143. Nine-week-old male and female mice were fasted for 6 
hours before the start of  the study and were provided water ad libitum. Mice were injected i.p. with a single 
bolus of  either 28 mg/kg of  the calcilytic NPS 2143 (Tocris Bioscience), diluted in 20% (2-hydroxypro-
pyl)-β-cyclodextrin (Sigma-Aldrich) or an equal volume of  20% (2-hydroxypropyl)-β-cyclodextrin as the 
vehicle control. The dose of  30 mg/kg of  the calcilytic NPS 2143 was previously shown to be effective in 
mouse models (21). Blood was taken from the superficial temporal vein at baseline, 4, and 24 hours after 
injection, and ionized calcium, PTH, and phosphate were measured as described (43). Ionized calcium 
values were corrected for pH. Spot urine was collected at baseline and, 4 hours after injection, was analyzed 
for calcium, phosphate, and creatinine (Stanbio Laboratory) (43).
Treatment of  mice with YM-254890. Twelve-week-old male and female mice were fasted for 6 hours prior 
to the study and for the duration of  the experiment, but water was provided ad libitum. Based on limited 
dose response studies (data not shown), mice were injected i.p. with either 0.15 mg/kg of  the selective Gα11/q 
inhibitor YM-254890 (24), which was diluted in 0.27% DMSO, or an equal volume of  0.27% DMSO as the 
vehicle control. Blood was taken from the superficial temporal vein at baseline, 4, and 24 hours after injec-
tion, and ionized calcium, PTH, and phosphorous were measured as previously described (43). Spot urine 
was collected and analyzed for calcium, phosphate, and creatinine at baseline and 4 hours after injection 
(43). The FEICa was calculated by the equation: urine calcium/(urine creatinine × blood calcium) (44).
Statistics. Data were analyzed using Microsoft Excel 2011 and GraphPad Prism 6.0. The results are 
expressed as mean ± SD. When comparing 2 values, the Student’s t test was performed (2-tailed, equal 
variances), and a P <0.05 was considered statistically significant. When comparing more than 2 samples as 
in the baseline measurements, an ANOVA test was used with Tukey’s multiple corrections test to compare 
the 3 groups.
Study Approval. This study was approved by the Institutional Animal Care and Use Committee 
(IACUC) of  MGH.
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